Metabolic imaging using F-18 Fluorodeoxyglucose (FDG) PET/CT has become the cornerstone of oncologic imaging and has been shown to be useful in tumor staging and follow-up. FDG PET/CT has also proven useful in predicting prognosis and treatment response. In certain diseases, such as lymphoma, higher FDG uptake is an indication of a higher grade malignancy. It is the most accurate, non-invasive imaging modality to differentiate between a benign and malignant tumour, sparing patients the painful diagnostic surgeries and suggesting treatment options earlier in the course of the disease.
PET & Fused PET/CT images in a case of Hodgkin’s Lymphoma
- *NSCLC pre-therapy
- *NSCLC disease progression
*NSCLC – Non-Small Cell Lung Cancer
PET & Fused PET/CT scan in patient with oesophageal cancer
PET & Fused PET/CT images in a case of wide spread of metastases
We provide non-FDG PET/CT scans that are particularly effective for the molecular imaging of specific diseases.
C-11 Acetate PET/CT
A combination of PET examinations with FDG and 11C-Acetate is shown to have an incremental value when compared to single tracer-imaging in the diagnosis for liver cancer.
C11-Acetate: Tumor identified in liver
18F FDG: No Tumour visualized
F-18 Choline PET/CT
F18-Fluoromethylcholine (FCH) has proven to be superior to FDG in the detection of metastatic disease, including that of extensive bone metastases from prostate cancer.
Compared with the FCH PET scan, the FDG PET scan under-estimates the bone metastic disease burden
Gallium-68 PSMA PET/CT
PET Imaging with 68Ga-PSMA can present lesions suspicious for prostate cancer with excellent contrast and a high detection rate even when the level of prostate specific antigen is low. It allows the identification of benign and malignant prostatic epithelium and may be a potentially valuable marker in the treatment of patients with prostate cancer.
Gallium-68 DOTANOC/DOTATOC PET/CT
PET imaging using Gallium-68 (Ga-68) labeled compound -DOTATATE offers higher resolution and improved pharmacokinetics compared with somatostatin receptor scintigraphy, with promising results in the detection of SST receptor-expressing tumors.
Sodium Fluoride PET/CT bone scan has greater sensitivity and specificity than other nuclear medicine techniques. The higher photon flux with NaF-18 compared to traditional bone scanning agents makes the lesions more conspicuous and easier to see. This translates to detection of relatively higher number of lesions on PET bone scan.